Tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Pharmacology: Pharmacodynamics under Actions for important information on the populations for which efficacy has been established).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
